证券记录 · 已归档季度
RYTM
Rhythm Pharmaceuticals, Inc. · Healthcare · Biotechnology
20被追踪持有人
+1Δ持有人
28.88M持有股份
$2.92B报告持仓市值
+2新建仓位
−2清仓
动量输入（同类管理人）：
持有人广度 +5.3% ·
股份流向 +5.1% ·
净新建仓位 0.0%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 112 | +7 | 44.38M | $4.90B | +14 | −8 |
| Q1 2026 | 109 | +6 | 41.83M | $3.64B | +11 | −6 |
| Q4 2025 | 102 | 0 | 43.14M | $4.62B | +3 | −2 |
| Q3 2025 | 20 | +1 | 28.88M | $2.92B | +2 | −2 |
| Q2 2025 | 17 | 0 | 22.96M | $1.45B | +1 | −1 |
| Q1 2025 | 14 | +2 | 11.52M | $610.22M | +2 | n/a |
| Q4 2024 | 12 | 0 | 11.40M | $638.39M | n/a | n/a |
| Q3 2024 | 11 | +3 | 9.71M | $508.75M | +3 | n/a |
| Q2 2024 | 8 | n/a | 9.56M | $392.54M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (被动) | 6.30M | +0.6% | $636.46M | 0.0% | ▲ Add | 2 | SEC ↗ ×16 |
| 2 | The Vanguard Group ✦ (被动) | 5.00M | +39.2% | $504.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | PRIMECAP Management ✦ | 4.26M | -12.6% | $430.51M | 0.3% | ▼ Trim | 6 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 2.38M | n/a | $239.97M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 5 | Fidelity (FMR) ✦ | 2.15M | +9.8% | $216.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 6 | State Street Global Advisors ✦ (被动) | 2.03M | +6.3% | $204.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | Goldman Sachs Group ✦ | 1.89M | n/a | $191.24M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | T. Rowe Price ✦ | 1.40M | +4.4% | $141.38M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Geode Capital Management ✦ (被动) | 1.36M | +3.9% | $137.65M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 546.59K | +73.6% | $55.20M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 11 | Adage Capital Partners ✦ | 544.00K | +59.5% | $54.94M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Morgan Stanley ✦ | 465.19K | n/a | $46.98M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 13 | Marshall Wace ✦ | 171.83K | -54.3% | $17.35M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Millennium Management ✦ | 133.16K | -32.8% | $13.45M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 132.63K | 新增 | $13.39M | 0.0% | New | 1 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 79.78K | +62.7% | $8.06M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 17 | Wellington Management ✦ | 24.48K | +9.2% | $2.47M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 18 | Arrowstreet Capital ✦ | 6.31K | 新增 | $636,944 | 0.0% | New | 1 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 4.86K | +0.1% | $490,306 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 3.58K | -85.2% | $362,049 | 0.0% | ▼ Trim | 5 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Citadel Advisors | $13.39M | 0.0% |
| Arrowstreet Capital | $636,944 | 0.0% |
已清仓
| Norges Bank | $13.10M | 曾为 0.0% |
| Point72 Asset Management | $10.79M | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 284 持有人, 72.02M 股份, $6.12B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 14
Meeker David P
Officer, Director · 1.82K 股 · $189,965
Sep 14
Meeker David P
Officer, Director · 8.70K 股 · $899,634
Sep 14
Meeker David P
Officer, Director · 30.75K 股 · $3.15M
Sep 14
Meeker David P
Officer, Director · 6.44K 股 · $655,145
Sep 14
Meeker David P
Officer, Director · 2.30K 股 · $241,937
Aug 31
Smith Hunter C
Officer · 11.51K 股 · $1.21M
Aug 31
Smith Hunter C
Officer · 23.07K 股 · $2.41M
Aug 31
Smith Hunter C
Officer · 28.19K 股 · $2.99M
Aug 13
Garfield Alastair
Officer · 2.01K 股 · $233,031
Aug 13
Garfield Alastair
Officer · 1.56K 股 · $182,170
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Oct 13
SC 13G: JPMORGAN CHASE & CO
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据